


**NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Dalfampridine. [Updated 2019 Jun 3]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



# **Dalfampridine**

Revised: June 3, 2019.

CASRN: 504-24-5



# **Drug Levels and Effects**

## **Summary of Use during Lactation**

Because no information is available on the use of dalfampridine during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

### **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

#### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

## **Substance Identification**

#### **Substance Name**

Dalfampridine

## **CAS Registry Number**

504-24-5

## **Drug Class**

Breastfeeding

Lactation

Neuromuscular Agents

Potassium Channel Blockers